nodes	percent_of_prediction	percent_of_DWPC	metapath
Danazol—CYP3A4—Imiquimod—skin cancer	0.111	0.292	CbGbCtD
Danazol—CYP3A4—Temozolomide—skin cancer	0.111	0.292	CbGbCtD
Danazol—CYP3A4—Vismodegib—skin cancer	0.0771	0.202	CbGbCtD
Danazol—CYP3A4—Vemurafenib—skin cancer	0.0609	0.16	CbGbCtD
Danazol—AR—scrotum—skin cancer	0.0286	0.123	CbGeAlD
Danazol—CYP3A4—Docetaxel—skin cancer	0.0209	0.0548	CbGbCtD
Danazol—CCL2—skin epidermis—skin cancer	0.0166	0.0713	CbGeAlD
Danazol—SHBG—hindlimb—skin cancer	0.0136	0.0583	CbGeAlD
Danazol—AR—penis—skin cancer	0.0129	0.0554	CbGeAlD
Danazol—Pleuritic pain—Bleomycin—skin cancer	0.0121	0.0426	CcSEcCtD
Danazol—CCL2—endothelium—skin cancer	0.0121	0.0517	CbGeAlD
Danazol—CCL2—blood vessel—skin cancer	0.0111	0.0477	CbGeAlD
Danazol—CCL2—nipple—skin cancer	0.00804	0.0345	CbGeAlD
Danazol—CCL2—neck—skin cancer	0.00795	0.0341	CbGeAlD
Danazol—Amenorrhoea—Vismodegib—skin cancer	0.00741	0.026	CcSEcCtD
Danazol—Pigmentation disorder—Temozolomide—skin cancer	0.00616	0.0216	CcSEcCtD
Danazol—PGR—blood vessel—skin cancer	0.00584	0.0251	CbGeAlD
Danazol—CCL2—connective tissue—skin cancer	0.0057	0.0245	CbGeAlD
Danazol—CCL2—epithelium—skin cancer	0.00541	0.0232	CbGeAlD
Danazol—GNRHR—female reproductive system—skin cancer	0.00515	0.0221	CbGeAlD
Danazol—CCL2—skin of body—skin cancer	0.00515	0.0221	CbGeAlD
Danazol—CCL2—mammalian vulva—skin cancer	0.0047	0.0201	CbGeAlD
Danazol—SHBG—neck—skin cancer	0.00464	0.0199	CbGeAlD
Danazol—ESR1—blood vessel—skin cancer	0.00457	0.0196	CbGeAlD
Danazol—Abdominal pain upper—Vismodegib—skin cancer	0.00432	0.0152	CcSEcCtD
Danazol—GNRHR—head—skin cancer	0.0043	0.0185	CbGeAlD
Danazol—Interstitial pneumonia—Temozolomide—skin cancer	0.00426	0.0149	CcSEcCtD
Danazol—PGR—nipple—skin cancer	0.00423	0.0181	CbGeAlD
Danazol—CCL2—lymphoid tissue—skin cancer	0.00417	0.0179	CbGeAlD
Danazol—CCL2—female reproductive system—skin cancer	0.00402	0.0173	CbGeAlD
Danazol—Interstitial lung disease—Bleomycin—skin cancer	0.00344	0.0121	CcSEcCtD
Danazol—AR—nipple—skin cancer	0.00337	0.0144	CbGeAlD
Danazol—CCL2—head—skin cancer	0.00336	0.0144	CbGeAlD
Danazol—Photosensitivity—Vemurafenib—skin cancer	0.00333	0.0117	CcSEcCtD
Danazol—SHBG—connective tissue—skin cancer	0.00333	0.0143	CbGeAlD
Danazol—GNRHR—Peptide GPCRs—MC1R—skin cancer	0.0033	0.0328	CbGpPWpGaD
Danazol—ESR1—neck—skin cancer	0.00327	0.014	CbGeAlD
Danazol—PGR—connective tissue—skin cancer	0.003	0.0129	CbGeAlD
Danazol—Interstitial lung disease—Temozolomide—skin cancer	0.00291	0.0102	CcSEcCtD
Danazol—Alopecia—Vismodegib—skin cancer	0.00289	0.0101	CcSEcCtD
Danazol—Hepatic function abnormal—Imiquimod—skin cancer	0.00285	0.01	CcSEcCtD
Danazol—PGR—epithelium—skin cancer	0.00284	0.0122	CbGeAlD
Danazol—Interstitial pneumonia—Docetaxel—skin cancer	0.00283	0.00993	CcSEcCtD
Danazol—PGR—Ovarian Infertility Genes—MLH1—skin cancer	0.00278	0.0276	CbGpPWpGaD
Danazol—Back pain—Vismodegib—skin cancer	0.00275	0.00967	CcSEcCtD
Danazol—Muscle spasms—Vismodegib—skin cancer	0.00274	0.00961	CcSEcCtD
Danazol—Nasal congestion—Imiquimod—skin cancer	0.00273	0.0096	CcSEcCtD
Danazol—CYP19A1—connective tissue—skin cancer	0.0027	0.0116	CbGeAlD
Danazol—CCL2—Spinal Cord Injury—CSPG4—skin cancer	0.0026	0.0259	CbGpPWpGaD
Danazol—Eosinophilia—Vemurafenib—skin cancer	0.0025	0.00877	CcSEcCtD
Danazol—Migraine—Imiquimod—skin cancer	0.00245	0.0086	CcSEcCtD
Danazol—Arthralgia—Vismodegib—skin cancer	0.00242	0.00851	CcSEcCtD
Danazol—AR—connective tissue—skin cancer	0.00239	0.0102	CbGeAlD
Danazol—Irritability—Imiquimod—skin cancer	0.00238	0.00834	CcSEcCtD
Danazol—CCL2—lymph node—skin cancer	0.00235	0.0101	CbGeAlD
Danazol—SHBG—female reproductive system—skin cancer	0.00235	0.0101	CbGeAlD
Danazol—ESR1—connective tissue—skin cancer	0.00234	0.0101	CbGeAlD
Danazol—Amenorrhoea—Temozolomide—skin cancer	0.00234	0.00821	CcSEcCtD
Danazol—Photosensitivity reaction—Vemurafenib—skin cancer	0.0023	0.00809	CcSEcCtD
Danazol—AR—epithelium—skin cancer	0.00227	0.00973	CbGeAlD
Danazol—Stevens-Johnson syndrome—Vemurafenib—skin cancer	0.00223	0.00783	CcSEcCtD
Danazol—ESR1—epithelium—skin cancer	0.00222	0.00955	CbGeAlD
Danazol—PGR—lymphoid tissue—skin cancer	0.00219	0.0094	CbGeAlD
Danazol—AR—skin of body—skin cancer	0.00216	0.00925	CbGeAlD
Danazol—Musculoskeletal discomfort—Vismodegib—skin cancer	0.00212	0.00743	CcSEcCtD
Danazol—PGR—female reproductive system—skin cancer	0.00211	0.00907	CbGeAlD
Danazol—Dyspepsia—Vismodegib—skin cancer	0.00205	0.00718	CcSEcCtD
Danazol—Leukocytosis—Fluorouracil—skin cancer	0.00202	0.00708	CcSEcCtD
Danazol—Fatigue—Vismodegib—skin cancer	0.002	0.00703	CcSEcCtD
Danazol—Constipation—Vismodegib—skin cancer	0.00199	0.00697	CcSEcCtD
Danazol—AR—mammalian vulva—skin cancer	0.00197	0.00844	CbGeAlD
Danazol—Photosensitivity reaction—Imiquimod—skin cancer	0.00197	0.0069	CcSEcCtD
Danazol—Interstitial lung disease—Docetaxel—skin cancer	0.00193	0.00678	CcSEcCtD
Danazol—Erythema multiforme—Vemurafenib—skin cancer	0.00191	0.00671	CcSEcCtD
Danazol—Stevens-Johnson syndrome—Imiquimod—skin cancer	0.0019	0.00668	CcSEcCtD
Danazol—CYP19A1—female reproductive system—skin cancer	0.0019	0.00816	CbGeAlD
Danazol—Throat sore—Docetaxel—skin cancer	0.0019	0.00666	CcSEcCtD
Danazol—Acute coronary syndrome—Imiquimod—skin cancer	0.00189	0.00664	CcSEcCtD
Danazol—GNRHR—GPCRs, Other—SMO—skin cancer	0.00189	0.0188	CbGpPWpGaD
Danazol—Myocardial infarction—Imiquimod—skin cancer	0.00188	0.0066	CcSEcCtD
Danazol—Oropharyngeal discomfort—Docetaxel—skin cancer	0.00188	0.0066	CcSEcCtD
Danazol—CYP19A1—Ovarian Infertility Genes—MLH1—skin cancer	0.00182	0.0181	CbGpPWpGaD
Danazol—Chills—Vemurafenib—skin cancer	0.00181	0.00636	CcSEcCtD
Danazol—Alopecia—Vemurafenib—skin cancer	0.00179	0.00627	CcSEcCtD
Danazol—ESR1—Signaling mediated by p38-alpha and p38-beta—MITF—skin cancer	0.00177	0.0176	CbGpPWpGaD
Danazol—PGR—head—skin cancer	0.00177	0.00758	CbGeAlD
Danazol—AR—lymphoid tissue—skin cancer	0.00175	0.00749	CbGeAlD
Danazol—Haemoglobin—Imiquimod—skin cancer	0.00173	0.00608	CcSEcCtD
Danazol—Haemorrhage—Imiquimod—skin cancer	0.00172	0.00605	CcSEcCtD
Danazol—ESR1—lymphoid tissue—skin cancer	0.00171	0.00735	CbGeAlD
Danazol—AR—FOXA1 transcription factor network—SHH—skin cancer	0.00171	0.017	CbGpPWpGaD
Danazol—Back pain—Vemurafenib—skin cancer	0.0017	0.00597	CcSEcCtD
Danazol—CCL2—Peptide ligand-binding receptors—MC1R—skin cancer	0.0017	0.0169	CbGpPWpGaD
Danazol—Gastroenteritis—Temozolomide—skin cancer	0.00168	0.00591	CcSEcCtD
Danazol—AR—female reproductive system—skin cancer	0.00168	0.00722	CbGeAlD
Danazol—Asthenia—Vismodegib—skin cancer	0.00167	0.00585	CcSEcCtD
Danazol—CCL2—Validated transcriptional targets of AP1 family members Fra1 and Fra2—CDKN2A—skin cancer	0.00167	0.0166	CbGpPWpGaD
Danazol—Visual impairment—Imiquimod—skin cancer	0.00166	0.00583	CcSEcCtD
Danazol—ESR1—female reproductive system—skin cancer	0.00165	0.00709	CbGeAlD
Danazol—Pruritus—Vismodegib—skin cancer	0.00164	0.00577	CcSEcCtD
Danazol—ESR1—FOXM1 transcription factor network—XRCC1—skin cancer	0.00164	0.0163	CbGpPWpGaD
Danazol—Nasal congestion—Temozolomide—skin cancer	0.00164	0.00575	CcSEcCtD
Danazol—Erythema multiforme—Imiquimod—skin cancer	0.00163	0.00572	CcSEcCtD
Danazol—Flushing—Imiquimod—skin cancer	0.0016	0.00561	CcSEcCtD
Danazol—CYP19A1—head—skin cancer	0.00159	0.00682	CbGeAlD
Danazol—Photosensitivity—Fluorouracil—skin cancer	0.00157	0.0055	CcSEcCtD
Danazol—CCL2—Ectoderm Differentiation—SHH—skin cancer	0.00156	0.0155	CbGpPWpGaD
Danazol—Amenorrhoea—Docetaxel—skin cancer	0.00156	0.00546	CcSEcCtD
Danazol—Chills—Imiquimod—skin cancer	0.00155	0.00543	CcSEcCtD
Danazol—Alopecia—Imiquimod—skin cancer	0.00152	0.00534	CcSEcCtD
Danazol—Oropharyngeal pain—Docetaxel—skin cancer	0.0015	0.00528	CcSEcCtD
Danazol—Arthralgia—Vemurafenib—skin cancer	0.0015	0.00526	CcSEcCtD
Danazol—Vomiting—Vismodegib—skin cancer	0.00148	0.00519	CcSEcCtD
Danazol—Affect lability—Temozolomide—skin cancer	0.00147	0.00516	CcSEcCtD
Danazol—Rash—Vismodegib—skin cancer	0.00147	0.00514	CcSEcCtD
Danazol—Dermatitis—Vismodegib—skin cancer	0.00146	0.00514	CcSEcCtD
Danazol—Back pain—Imiquimod—skin cancer	0.00145	0.00509	CcSEcCtD
Danazol—SHBG—Nongenotropic Androgen signaling—HRAS—skin cancer	0.00145	0.0144	CbGpPWpGaD
Danazol—Mood swings—Temozolomide—skin cancer	0.00141	0.00496	CcSEcCtD
Danazol—PGR—Ovarian Infertility Genes—CDK4—skin cancer	0.00141	0.0141	CbGpPWpGaD
Danazol—AR—head—skin cancer	0.00141	0.00604	CbGeAlD
Danazol—ESR1—head—skin cancer	0.00138	0.00593	CbGeAlD
Danazol—Nausea—Vismodegib—skin cancer	0.00138	0.00484	CcSEcCtD
Danazol—Syncope—Imiquimod—skin cancer	0.00135	0.00472	CcSEcCtD
Danazol—Acute coronary syndrome—Bleomycin—skin cancer	0.00134	0.00472	CcSEcCtD
Danazol—Myocardial infarction—Bleomycin—skin cancer	0.00134	0.00469	CcSEcCtD
Danazol—Palpitations—Imiquimod—skin cancer	0.00133	0.00465	CcSEcCtD
Danazol—ESR1—FOXA1 transcription factor network—SHH—skin cancer	0.00132	0.0131	CbGpPWpGaD
Danazol—Loss of consciousness—Imiquimod—skin cancer	0.00132	0.00463	CcSEcCtD
Danazol—Irritability—Fluorouracil—skin cancer	0.00131	0.00461	CcSEcCtD
Danazol—Musculoskeletal discomfort—Vemurafenib—skin cancer	0.00131	0.00459	CcSEcCtD
Danazol—Haematuria—Bleomycin—skin cancer	0.0013	0.00456	CcSEcCtD
Danazol—Convulsion—Imiquimod—skin cancer	0.0013	0.00456	CcSEcCtD
Danazol—Fluid retention—Docetaxel—skin cancer	0.0013	0.00456	CcSEcCtD
Danazol—Hypertension—Imiquimod—skin cancer	0.0013	0.00455	CcSEcCtD
Danazol—Arthralgia—Imiquimod—skin cancer	0.00128	0.00448	CcSEcCtD
Danazol—Anxiety—Imiquimod—skin cancer	0.00127	0.00447	CcSEcCtD
Danazol—Stevens-Johnson syndrome—Dactinomycin—skin cancer	0.00126	0.00443	CcSEcCtD
Danazol—Fatigue—Vemurafenib—skin cancer	0.00124	0.00434	CcSEcCtD
Danazol—PGR—lymph node—skin cancer	0.00124	0.0053	CbGeAlD
Danazol—Haemoglobin—Bleomycin—skin cancer	0.00123	0.00432	CcSEcCtD
Danazol—Constipation—Vemurafenib—skin cancer	0.00123	0.00431	CcSEcCtD
Danazol—Oedema—Imiquimod—skin cancer	0.00122	0.0043	CcSEcCtD
Danazol—Haemorrhage—Bleomycin—skin cancer	0.00122	0.0043	CcSEcCtD
Danazol—CCL2—GMCSF-mediated signaling events—NRAS—skin cancer	0.00121	0.0121	CbGpPWpGaD
Danazol—Shock—Imiquimod—skin cancer	0.0012	0.00423	CcSEcCtD
Danazol—CCL2—GPCR ligand binding—PTCH2—skin cancer	0.0012	0.0119	CbGpPWpGaD
Danazol—Tachycardia—Imiquimod—skin cancer	0.0012	0.00419	CcSEcCtD
Danazol—Hyperhidrosis—Imiquimod—skin cancer	0.00118	0.00415	CcSEcCtD
Danazol—AR—Regulation of nuclear beta catenin signaling and target gene transcription—MITF—skin cancer	0.00118	0.0118	CbGpPWpGaD
Danazol—Photosensitivity reaction—Temozolomide—skin cancer	0.00118	0.00413	CcSEcCtD
Danazol—Eosinophilia—Fluorouracil—skin cancer	0.00118	0.00413	CcSEcCtD
Danazol—Weight increased—Temozolomide—skin cancer	0.00117	0.00412	CcSEcCtD
Danazol—Stevens-Johnson syndrome—Temozolomide—skin cancer	0.00114	0.004	CcSEcCtD
Danazol—CCL2—Class A/1 (Rhodopsin-like receptors)—MC1R—skin cancer	0.00114	0.0113	CbGpPWpGaD
Danazol—Flushing—Bleomycin—skin cancer	0.00114	0.00399	CcSEcCtD
Danazol—Body temperature increased—Vemurafenib—skin cancer	0.00114	0.00398	CcSEcCtD
Danazol—Musculoskeletal discomfort—Imiquimod—skin cancer	0.00112	0.00391	CcSEcCtD
Danazol—CYP19A1—lymph node—skin cancer	0.00111	0.00477	CbGeAlD
Danazol—Paraesthesia—Imiquimod—skin cancer	0.0011	0.00386	CcSEcCtD
Danazol—Chills—Bleomycin—skin cancer	0.0011	0.00386	CcSEcCtD
Danazol—GNRHR—GPCR ligand binding—PTCH2—skin cancer	0.0011	0.0109	CbGpPWpGaD
Danazol—Photosensitivity reaction—Fluorouracil—skin cancer	0.00109	0.00381	CcSEcCtD
Danazol—Alopecia—Bleomycin—skin cancer	0.00108	0.0038	CcSEcCtD
Danazol—Erythema multiforme—Dactinomycin—skin cancer	0.00108	0.00379	CcSEcCtD
Danazol—Dyspepsia—Imiquimod—skin cancer	0.00108	0.00378	CcSEcCtD
Danazol—Flushing—Dactinomycin—skin cancer	0.00106	0.00372	CcSEcCtD
Danazol—Fatigue—Imiquimod—skin cancer	0.00106	0.0037	CcSEcCtD
Danazol—AR—Integrated Breast Cancer Pathway—XRCC3—skin cancer	0.00105	0.0105	CbGpPWpGaD
Danazol—Visual disturbance—Docetaxel—skin cancer	0.00105	0.00368	CcSEcCtD
Danazol—Acute coronary syndrome—Fluorouracil—skin cancer	0.00104	0.00367	CcSEcCtD
Danazol—CCL2—GMCSF-mediated signaling events—KRAS—skin cancer	0.00104	0.0104	CbGpPWpGaD
Danazol—GNRHR—Class A/1 (Rhodopsin-like receptors)—MC1R—skin cancer	0.00104	0.0104	CbGpPWpGaD
Danazol—Myocardial infarction—Fluorouracil—skin cancer	0.00104	0.00365	CcSEcCtD
Danazol—Haemoglobin—Temozolomide—skin cancer	0.00104	0.00364	CcSEcCtD
Danazol—Haemorrhage—Temozolomide—skin cancer	0.00103	0.00362	CcSEcCtD
Danazol—Asthenia—Vemurafenib—skin cancer	0.00103	0.00361	CcSEcCtD
Danazol—Chills—Dactinomycin—skin cancer	0.00102	0.0036	CcSEcCtD
Danazol—Pruritus—Vemurafenib—skin cancer	0.00102	0.00356	CcSEcCtD
Danazol—Alopecia—Dactinomycin—skin cancer	0.00101	0.00354	CcSEcCtD
Danazol—CCL2—AP-1 transcription factor network—CDKN2A—skin cancer	0.001	0.00995	CbGpPWpGaD
Danazol—Visual impairment—Temozolomide—skin cancer	0.000995	0.00349	CcSEcCtD
Danazol—CCL2—Metabolism of proteins—EXOC2—skin cancer	0.000992	0.00986	CbGpPWpGaD
Danazol—AR—lymph node—skin cancer	0.000985	0.00423	CbGeAlD
Danazol—Migraine—Docetaxel—skin cancer	0.000977	0.00343	CcSEcCtD
Danazol—Erythema multiforme—Temozolomide—skin cancer	0.000977	0.00343	CcSEcCtD
Danazol—Urticaria—Imiquimod—skin cancer	0.000973	0.00341	CcSEcCtD
Danazol—Body temperature increased—Imiquimod—skin cancer	0.000968	0.0034	CcSEcCtD
Danazol—ESR1—lymph node—skin cancer	0.000967	0.00415	CbGeAlD
Danazol—Flushing—Temozolomide—skin cancer	0.000959	0.00336	CcSEcCtD
Danazol—Haemoglobin—Fluorouracil—skin cancer	0.000956	0.00336	CcSEcCtD
Danazol—ESR1—Estrogen signaling pathway—BRAF—skin cancer	0.000956	0.0095	CbGpPWpGaD
Danazol—Leukopenia—Bleomycin—skin cancer	0.000954	0.00335	CcSEcCtD
Danazol—Haemorrhage—Fluorouracil—skin cancer	0.000952	0.00334	CcSEcCtD
Danazol—Dizziness—Vemurafenib—skin cancer	0.000949	0.00333	CcSEcCtD
Danazol—Chills—Temozolomide—skin cancer	0.000927	0.00325	CcSEcCtD
Danazol—CYP19A1—Ovarian Infertility Genes—CDK4—skin cancer	0.000926	0.00921	CbGpPWpGaD
Danazol—CYP3A4—female reproductive system—skin cancer	0.000922	0.00396	CbGeAlD
Danazol—Vomiting—Vemurafenib—skin cancer	0.000913	0.0032	CcSEcCtD
Danazol—Alopecia—Temozolomide—skin cancer	0.000913	0.0032	CcSEcCtD
Danazol—CYP19A1—Integrated Breast Cancer Pathway—XRCC3—skin cancer	0.000907	0.00902	CbGpPWpGaD
Danazol—Abdominal pain upper—Docetaxel—skin cancer	0.000907	0.00318	CcSEcCtD
Danazol—Rash—Vemurafenib—skin cancer	0.000905	0.00318	CcSEcCtD
Danazol—Dermatitis—Vemurafenib—skin cancer	0.000904	0.00317	CcSEcCtD
Danazol—Headache—Vemurafenib—skin cancer	0.000899	0.00316	CcSEcCtD
Danazol—Cramp muscle—Docetaxel—skin cancer	0.000894	0.00314	CcSEcCtD
Danazol—Leukopenia—Dactinomycin—skin cancer	0.00089	0.00312	CcSEcCtD
Danazol—CCL2—GMCSF-mediated signaling events—HRAS—skin cancer	0.000887	0.00882	CbGpPWpGaD
Danazol—Asthenia—Imiquimod—skin cancer	0.000879	0.00308	CcSEcCtD
Danazol—Oedema—Bleomycin—skin cancer	0.00087	0.00305	CcSEcCtD
Danazol—Back pain—Temozolomide—skin cancer	0.00087	0.00305	CcSEcCtD
Danazol—CCL2—GPCR ligand binding—MC1R—skin cancer	0.000867	0.00862	CbGpPWpGaD
Danazol—Pruritus—Imiquimod—skin cancer	0.000866	0.00304	CcSEcCtD
Danazol—CCL2—Spinal Cord Injury—CDK4—skin cancer	0.000863	0.00858	CbGpPWpGaD
Danazol—AR—Regulation of nuclear SMAD2/3 signaling—FOXO4—skin cancer	0.000857	0.00852	CbGpPWpGaD
Danazol—Nausea—Vemurafenib—skin cancer	0.000853	0.00299	CcSEcCtD
Danazol—Thrombocytopenia—Bleomycin—skin cancer	0.000852	0.00299	CcSEcCtD
Danazol—CCL2—IL23-mediated signaling events—IL6—skin cancer	0.000849	0.00845	CbGpPWpGaD
Danazol—CCL2—Validated transcriptional targets of AP1 family members Fra1 and Fra2—IL6—skin cancer	0.000849	0.00845	CbGpPWpGaD
Danazol—Vision blurred—Temozolomide—skin cancer	0.000847	0.00297	CcSEcCtD
Danazol—Tremor—Temozolomide—skin cancer	0.000842	0.00296	CcSEcCtD
Danazol—Alopecia—Fluorouracil—skin cancer	0.000841	0.00295	CcSEcCtD
Danazol—ESR1—Integrated Breast Cancer Pathway—XRCC3—skin cancer	0.000812	0.00807	CbGpPWpGaD
Danazol—Oedema—Dactinomycin—skin cancer	0.000811	0.00285	CcSEcCtD
Danazol—Dizziness—Imiquimod—skin cancer	0.00081	0.00284	CcSEcCtD
Danazol—Vertigo—Temozolomide—skin cancer	0.000808	0.00283	CcSEcCtD
Danazol—Leukopenia—Temozolomide—skin cancer	0.000805	0.00282	CcSEcCtD
Danazol—Palpitations—Temozolomide—skin cancer	0.000795	0.00279	CcSEcCtD
Danazol—Thrombocytopenia—Dactinomycin—skin cancer	0.000794	0.00279	CcSEcCtD
Danazol—GNRHR—GPCR ligand binding—MC1R—skin cancer	0.000793	0.00788	CbGpPWpGaD
Danazol—Musculoskeletal discomfort—Bleomycin—skin cancer	0.000793	0.00278	CcSEcCtD
Danazol—Paraesthesia—Bleomycin—skin cancer	0.000781	0.00274	CcSEcCtD
Danazol—Weight increased—Docetaxel—skin cancer	0.000781	0.00274	CcSEcCtD
Danazol—Vision blurred—Fluorouracil—skin cancer	0.000781	0.00274	CcSEcCtD
Danazol—CCL2—Selenium Micronutrient Network—PTGS2—skin cancer	0.00078	0.00775	CbGpPWpGaD
Danazol—Convulsion—Temozolomide—skin cancer	0.000779	0.00273	CcSEcCtD
Danazol—Vomiting—Imiquimod—skin cancer	0.000779	0.00273	CcSEcCtD
Danazol—Hypertension—Temozolomide—skin cancer	0.000776	0.00272	CcSEcCtD
Danazol—Rash—Imiquimod—skin cancer	0.000772	0.00271	CcSEcCtD
Danazol—Dermatitis—Imiquimod—skin cancer	0.000771	0.00271	CcSEcCtD
Danazol—CCL2—TWEAK Signaling Pathway—IL6—skin cancer	0.000767	0.00763	CbGpPWpGaD
Danazol—Headache—Imiquimod—skin cancer	0.000767	0.00269	CcSEcCtD
Danazol—Arthralgia—Temozolomide—skin cancer	0.000765	0.00269	CcSEcCtD
Danazol—Anxiety—Temozolomide—skin cancer	0.000763	0.00268	CcSEcCtD
Danazol—Stevens-Johnson syndrome—Docetaxel—skin cancer	0.000759	0.00266	CcSEcCtD
Danazol—Acute coronary syndrome—Docetaxel—skin cancer	0.000754	0.00265	CcSEcCtD
Danazol—Myocardial infarction—Docetaxel—skin cancer	0.00075	0.00263	CcSEcCtD
Danazol—CCL2—Class A/1 (Rhodopsin-like receptors)—PTGER4—skin cancer	0.000749	0.00744	CbGpPWpGaD
Danazol—Jaundice—Docetaxel—skin cancer	0.000746	0.00262	CcSEcCtD
Danazol—CCL2—Signaling Pathways—RHOU—skin cancer	0.000744	0.0074	CbGpPWpGaD
Danazol—Leukopenia—Fluorouracil—skin cancer	0.000742	0.0026	CcSEcCtD
Danazol—Musculoskeletal discomfort—Dactinomycin—skin cancer	0.000739	0.00259	CcSEcCtD
Danazol—Oedema—Temozolomide—skin cancer	0.000734	0.00257	CcSEcCtD
Danazol—Nausea—Imiquimod—skin cancer	0.000727	0.00255	CcSEcCtD
Danazol—Thrombocytopenia—Temozolomide—skin cancer	0.000718	0.00252	CcSEcCtD
Danazol—Convulsion—Fluorouracil—skin cancer	0.000718	0.00252	CcSEcCtD
Danazol—Hyperhidrosis—Temozolomide—skin cancer	0.000709	0.00249	CcSEcCtD
Danazol—Fatigue—Dactinomycin—skin cancer	0.000699	0.00245	CcSEcCtD
Danazol—Urticaria—Bleomycin—skin cancer	0.000691	0.00242	CcSEcCtD
Danazol—Haemoglobin—Docetaxel—skin cancer	0.00069	0.00242	CcSEcCtD
Danazol—Body temperature increased—Bleomycin—skin cancer	0.000688	0.00241	CcSEcCtD
Danazol—Haemorrhage—Docetaxel—skin cancer	0.000687	0.00241	CcSEcCtD
Danazol—GNRHR—Class A/1 (Rhodopsin-like receptors)—PTGER4—skin cancer	0.000685	0.00681	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—RHOU—skin cancer	0.000681	0.00677	CbGpPWpGaD
Danazol—PGR—Signaling by ERBB4—FOXO4—skin cancer	0.00068	0.00676	CbGpPWpGaD
Danazol—AR—Integrated Breast Cancer Pathway—MSH2—skin cancer	0.000679	0.00675	CbGpPWpGaD
Danazol—Oedema—Fluorouracil—skin cancer	0.000676	0.00237	CcSEcCtD
Danazol—Musculoskeletal discomfort—Temozolomide—skin cancer	0.000669	0.00235	CcSEcCtD
Danazol—ESR1—FOXM1 transcription factor network—CDK4—skin cancer	0.000667	0.00663	CbGpPWpGaD
Danazol—CCL2—Oncostatin M Signaling Pathway—KRAS—skin cancer	0.000665	0.00661	CbGpPWpGaD
Danazol—Thrombocytopenia—Fluorouracil—skin cancer	0.000662	0.00232	CcSEcCtD
Danazol—Visual impairment—Docetaxel—skin cancer	0.000662	0.00232	CcSEcCtD
Danazol—ESR1—Regulation of nuclear SMAD2/3 signaling—FOXO4—skin cancer	0.00066	0.00656	CbGpPWpGaD
Danazol—Tachycardia—Fluorouracil—skin cancer	0.00066	0.00232	CcSEcCtD
Danazol—Paraesthesia—Temozolomide—skin cancer	0.000659	0.00231	CcSEcCtD
Danazol—CCL2—Vitamin B12 Metabolism—IL6—skin cancer	0.000657	0.00653	CbGpPWpGaD
Danazol—Erythema multiforme—Docetaxel—skin cancer	0.000649	0.00228	CcSEcCtD
Danazol—Dyspepsia—Temozolomide—skin cancer	0.000646	0.00227	CcSEcCtD
Danazol—Body temperature increased—Dactinomycin—skin cancer	0.000641	0.00225	CcSEcCtD
Danazol—Flushing—Docetaxel—skin cancer	0.000637	0.00224	CcSEcCtD
Danazol—Fatigue—Temozolomide—skin cancer	0.000633	0.00222	CcSEcCtD
Danazol—Constipation—Temozolomide—skin cancer	0.000627	0.0022	CcSEcCtD
Danazol—Asthenia—Bleomycin—skin cancer	0.000624	0.00219	CcSEcCtD
Danazol—CCL2—GPCR ligand binding—SHH—skin cancer	0.000618	0.00614	CbGpPWpGaD
Danazol—CCL2—Spinal Cord Injury—PTGS2—skin cancer	0.000617	0.00613	CbGpPWpGaD
Danazol—Chills—Docetaxel—skin cancer	0.000616	0.00216	CcSEcCtD
Danazol—Musculoskeletal discomfort—Fluorouracil—skin cancer	0.000616	0.00216	CcSEcCtD
Danazol—Pruritus—Bleomycin—skin cancer	0.000615	0.00216	CcSEcCtD
Danazol—CCL2—Signaling by GPCR—PTCH2—skin cancer	0.000615	0.00612	CbGpPWpGaD
Danazol—Paraesthesia—Fluorouracil—skin cancer	0.000607	0.00213	CcSEcCtD
Danazol—Alopecia—Docetaxel—skin cancer	0.000607	0.00213	CcSEcCtD
Danazol—Dyspepsia—Fluorouracil—skin cancer	0.000595	0.00209	CcSEcCtD
Danazol—CCL2—Oncostatin M Signaling Pathway—TP53—skin cancer	0.000591	0.00588	CbGpPWpGaD
Danazol—CCL2—GPCR ligand binding—PTCH1—skin cancer	0.000586	0.00582	CbGpPWpGaD
Danazol—CCL2—GPCR ligand binding—SMO—skin cancer	0.000586	0.00582	CbGpPWpGaD
Danazol—CCL2—TNF alpha Signaling Pathway—NRAS—skin cancer	0.000585	0.00582	CbGpPWpGaD
Danazol—CYP19A1—Integrated Breast Cancer Pathway—MSH2—skin cancer	0.000584	0.00581	CbGpPWpGaD
Danazol—CCL2—Folate Metabolism—TP53—skin cancer	0.000584	0.00581	CbGpPWpGaD
Danazol—Urticaria—Temozolomide—skin cancer	0.000583	0.00205	CcSEcCtD
Danazol—Asthenia—Dactinomycin—skin cancer	0.000582	0.00204	CcSEcCtD
Danazol—Body temperature increased—Temozolomide—skin cancer	0.00058	0.00204	CcSEcCtD
Danazol—Back pain—Docetaxel—skin cancer	0.000578	0.00203	CcSEcCtD
Danazol—AR—Regulation of nuclear beta catenin signaling and target gene transcription—TERT—skin cancer	0.000578	0.00575	CbGpPWpGaD
Danazol—Muscle spasms—Docetaxel—skin cancer	0.000575	0.00202	CcSEcCtD
Danazol—CCL2—GPCR ligand binding—PTGER4—skin cancer	0.00057	0.00567	CbGpPWpGaD
Danazol—CCL2—Oncostatin M Signaling Pathway—HRAS—skin cancer	0.000565	0.00562	CbGpPWpGaD
Danazol—GNRHR—GPCR ligand binding—SHH—skin cancer	0.000565	0.00562	CbGpPWpGaD
Danazol—GNRHR—Signaling by GPCR—PTCH2—skin cancer	0.000563	0.0056	CbGpPWpGaD
Danazol—CCL2—AP-1 transcription factor network—TP53—skin cancer	0.000557	0.00554	CbGpPWpGaD
Danazol—Vomiting—Bleomycin—skin cancer	0.000553	0.00194	CcSEcCtD
Danazol—ESR1—Signaling mediated by p38-alpha and p38-beta—PTGS2—skin cancer	0.000552	0.00549	CbGpPWpGaD
Danazol—Rash—Bleomycin—skin cancer	0.000548	0.00192	CcSEcCtD
Danazol—Dermatitis—Bleomycin—skin cancer	0.000548	0.00192	CcSEcCtD
Danazol—Urticaria—Fluorouracil—skin cancer	0.000537	0.00188	CcSEcCtD
Danazol—Syncope—Docetaxel—skin cancer	0.000536	0.00188	CcSEcCtD
Danazol—GNRHR—GPCR ligand binding—SMO—skin cancer	0.000536	0.00532	CbGpPWpGaD
Danazol—GNRHR—GPCR ligand binding—PTCH1—skin cancer	0.000536	0.00532	CbGpPWpGaD
Danazol—Leukopenia—Docetaxel—skin cancer	0.000535	0.00188	CcSEcCtD
Danazol—CCL2—Folate Metabolism—IL6—skin cancer	0.000535	0.00532	CbGpPWpGaD
Danazol—Body temperature increased—Fluorouracil—skin cancer	0.000534	0.00188	CcSEcCtD
Danazol—AR—Integrated Pancreatic Cancer Pathway—SHH—skin cancer	0.000529	0.00526	CbGpPWpGaD
Danazol—Palpitations—Docetaxel—skin cancer	0.000528	0.00185	CcSEcCtD
Danazol—Asthenia—Temozolomide—skin cancer	0.000526	0.00185	CcSEcCtD
Danazol—Loss of consciousness—Docetaxel—skin cancer	0.000526	0.00184	CcSEcCtD
Danazol—ESR1—Integrated Breast Cancer Pathway—MSH2—skin cancer	0.000523	0.0052	CbGpPWpGaD
Danazol—GNRHR—GPCR ligand binding—PTGER4—skin cancer	0.000521	0.00518	CbGpPWpGaD
Danazol—Pruritus—Temozolomide—skin cancer	0.000519	0.00182	CcSEcCtD
Danazol—Convulsion—Docetaxel—skin cancer	0.000518	0.00182	CcSEcCtD
Danazol—Nausea—Bleomycin—skin cancer	0.000517	0.00181	CcSEcCtD
Danazol—Hypertension—Docetaxel—skin cancer	0.000516	0.00181	CcSEcCtD
Danazol—Vomiting—Dactinomycin—skin cancer	0.000516	0.00181	CcSEcCtD
Danazol—AR—Regulation of nuclear SMAD2/3 signaling—CDK4—skin cancer	0.000512	0.00509	CbGpPWpGaD
Danazol—Rash—Dactinomycin—skin cancer	0.000512	0.00179	CcSEcCtD
Danazol—CCL2—AP-1 transcription factor network—IL6—skin cancer	0.00051	0.00507	CbGpPWpGaD
Danazol—ESR1—FOXM1 transcription factor network—CDKN2A—skin cancer	0.00051	0.00507	CbGpPWpGaD
Danazol—Arthralgia—Docetaxel—skin cancer	0.000509	0.00179	CcSEcCtD
Danazol—ESR1—ATF-2 transcription factor network—CDK4—skin cancer	0.000508	0.00505	CbGpPWpGaD
Danazol—ESR1—Regulation of Telomerase—TERT—skin cancer	0.000507	0.00504	CbGpPWpGaD
Danazol—CCL2—TNF alpha Signaling Pathway—KRAS—skin cancer	0.000504	0.00501	CbGpPWpGaD
Danazol—AR—Integrated Pancreatic Cancer Pathway—SMO—skin cancer	0.000502	0.00499	CbGpPWpGaD
Danazol—AR—Coregulation of Androgen receptor activity—CDKN2A—skin cancer	0.000491	0.00488	CbGpPWpGaD
Danazol—Oedema—Docetaxel—skin cancer	0.000488	0.00171	CcSEcCtD
Danazol—Dizziness—Temozolomide—skin cancer	0.000485	0.0017	CcSEcCtD
Danazol—Nausea—Dactinomycin—skin cancer	0.000482	0.00169	CcSEcCtD
Danazol—Shock—Docetaxel—skin cancer	0.00048	0.00168	CcSEcCtD
Danazol—Pruritus—Fluorouracil—skin cancer	0.000478	0.00168	CcSEcCtD
Danazol—Thrombocytopenia—Docetaxel—skin cancer	0.000478	0.00168	CcSEcCtD
Danazol—Tachycardia—Docetaxel—skin cancer	0.000476	0.00167	CcSEcCtD
Danazol—Vomiting—Temozolomide—skin cancer	0.000467	0.00164	CcSEcCtD
Danazol—Rash—Temozolomide—skin cancer	0.000463	0.00162	CcSEcCtD
Danazol—Dermatitis—Temozolomide—skin cancer	0.000462	0.00162	CcSEcCtD
Danazol—Headache—Temozolomide—skin cancer	0.00046	0.00161	CcSEcCtD
Danazol—AR—Nongenotropic Androgen signaling—HRAS—skin cancer	0.000449	0.00447	CbGpPWpGaD
Danazol—GNRHR—GPCR downstream signaling—MC1R—skin cancer	0.000448	0.00445	CbGpPWpGaD
Danazol—Dizziness—Fluorouracil—skin cancer	0.000447	0.00157	CcSEcCtD
Danazol—CCL2—Signaling by GPCR—MC1R—skin cancer	0.000445	0.00442	CbGpPWpGaD
Danazol—Musculoskeletal discomfort—Docetaxel—skin cancer	0.000445	0.00156	CcSEcCtD
Danazol—ESR1—Aryl Hydrocarbon Receptor—PTGS2—skin cancer	0.000443	0.00441	CbGpPWpGaD
Danazol—Paraesthesia—Docetaxel—skin cancer	0.000438	0.00154	CcSEcCtD
Danazol—Nausea—Temozolomide—skin cancer	0.000436	0.00153	CcSEcCtD
Danazol—Vomiting—Fluorouracil—skin cancer	0.00043	0.00151	CcSEcCtD
Danazol—Dyspepsia—Docetaxel—skin cancer	0.00043	0.00151	CcSEcCtD
Danazol—PGR—Signaling Pathways—RHOU—skin cancer	0.000429	0.00427	CbGpPWpGaD
Danazol—CCL2—TNF alpha Signaling Pathway—HRAS—skin cancer	0.000428	0.00426	CbGpPWpGaD
Danazol—Rash—Fluorouracil—skin cancer	0.000426	0.0015	CcSEcCtD
Danazol—Dermatitis—Fluorouracil—skin cancer	0.000426	0.00149	CcSEcCtD
Danazol—CCL2—Selenium Micronutrient Network—IL6—skin cancer	0.000425	0.00422	CbGpPWpGaD
Danazol—Headache—Fluorouracil—skin cancer	0.000424	0.00149	CcSEcCtD
Danazol—Fatigue—Docetaxel—skin cancer	0.000421	0.00148	CcSEcCtD
Danazol—Constipation—Docetaxel—skin cancer	0.000417	0.00146	CcSEcCtD
Danazol—CCL2—TNF alpha Signaling Pathway—IL6—skin cancer	0.00041	0.00408	CbGpPWpGaD
Danazol—ESR1—Integrated Pancreatic Cancer Pathway—SHH—skin cancer	0.000408	0.00405	CbGpPWpGaD
Danazol—GNRHR—Signaling by GPCR—MC1R—skin cancer	0.000407	0.00405	CbGpPWpGaD
Danazol—Nausea—Fluorouracil—skin cancer	0.000402	0.00141	CcSEcCtD
Danazol—ESR1—Signaling by ERBB4—FOXO4—skin cancer	0.000399	0.00397	CbGpPWpGaD
Danazol—AR—Regulation of nuclear beta catenin signaling and target gene transcription—CDKN2A—skin cancer	0.000395	0.00393	CbGpPWpGaD
Danazol—ESR1—Regulation of nuclear SMAD2/3 signaling—CDK4—skin cancer	0.000395	0.00392	CbGpPWpGaD
Danazol—ESR1—Integrated Pancreatic Cancer Pathway—SMO—skin cancer	0.000386	0.00384	CbGpPWpGaD
Danazol—Body temperature increased—Docetaxel—skin cancer	0.000386	0.00135	CcSEcCtD
Danazol—ESR1—Plasma membrane estrogen receptor signaling—NRAS—skin cancer	0.000378	0.00376	CbGpPWpGaD
Danazol—CCL2—Spinal Cord Injury—TP53—skin cancer	0.000367	0.00365	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—PTCH2—skin cancer	0.000363	0.00361	CbGpPWpGaD
Danazol—Asthenia—Docetaxel—skin cancer	0.00035	0.00123	CcSEcCtD
Danazol—CYP19A1—Metabolism of lipids and lipoproteins—PLIN2—skin cancer	0.000347	0.00345	CbGpPWpGaD
Danazol—Pruritus—Docetaxel—skin cancer	0.000345	0.00121	CcSEcCtD
Danazol—ESR1—Aryl Hydrocarbon Receptor—NRAS—skin cancer	0.000345	0.00343	CbGpPWpGaD
Danazol—ESR1—AP-1 transcription factor network—CDKN2A—skin cancer	0.000339	0.00337	CbGpPWpGaD
Danazol—CCL2—Spinal Cord Injury—IL6—skin cancer	0.000336	0.00334	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—PTCH2—skin cancer	0.000332	0.00331	CbGpPWpGaD
Danazol—ESR1—Signaling mediated by p38-alpha and p38-beta—TP53—skin cancer	0.000328	0.00327	CbGpPWpGaD
Danazol—ESR1—Plasma membrane estrogen receptor signaling—KRAS—skin cancer	0.000326	0.00324	CbGpPWpGaD
Danazol—Dizziness—Docetaxel—skin cancer	0.000323	0.00113	CcSEcCtD
Danazol—CCL2—Signaling by GPCR—SHH—skin cancer	0.000317	0.00315	CbGpPWpGaD
Danazol—AR—Integrated Breast Cancer Pathway—CDK4—skin cancer	0.000311	0.00309	CbGpPWpGaD
Danazol—Vomiting—Docetaxel—skin cancer	0.00031	0.00109	CcSEcCtD
Danazol—Rash—Docetaxel—skin cancer	0.000308	0.00108	CcSEcCtD
Danazol—Dermatitis—Docetaxel—skin cancer	0.000307	0.00108	CcSEcCtD
Danazol—Headache—Docetaxel—skin cancer	0.000306	0.00107	CcSEcCtD
Danazol—CCL2—Signaling by GPCR—SMO—skin cancer	0.0003	0.00299	CbGpPWpGaD
Danazol—CCL2—Signaling by GPCR—PTCH1—skin cancer	0.0003	0.00299	CbGpPWpGaD
Danazol—ESR1—Aryl Hydrocarbon Receptor—KRAS—skin cancer	0.000297	0.00295	CbGpPWpGaD
Danazol—GNRHR—GPCR downstream signaling—PTGER4—skin cancer	0.000295	0.00293	CbGpPWpGaD
Danazol—CCL2—Signaling by GPCR—PTGER4—skin cancer	0.000293	0.00291	CbGpPWpGaD
Danazol—GNRHR—Signaling by GPCR—SHH—skin cancer	0.00029	0.00288	CbGpPWpGaD
Danazol—Nausea—Docetaxel—skin cancer	0.00029	0.00102	CcSEcCtD
Danazol—ESR1—LKB1 signaling events—TP53—skin cancer	0.000279	0.00277	CbGpPWpGaD
Danazol—ESR1—Plasma membrane estrogen receptor signaling—HRAS—skin cancer	0.000277	0.00275	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—GLI2—skin cancer	0.000275	0.00274	CbGpPWpGaD
Danazol—AR—Integrated Breast Cancer Pathway—BRAF—skin cancer	0.000275	0.00274	CbGpPWpGaD
Danazol—GNRHR—Signaling by GPCR—SMO—skin cancer	0.000275	0.00273	CbGpPWpGaD
Danazol—GNRHR—Signaling by GPCR—PTCH1—skin cancer	0.000275	0.00273	CbGpPWpGaD
Danazol—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—skin cancer	0.000271	0.0027	CbGpPWpGaD
Danazol—CYP19A1—Integrated Breast Cancer Pathway—CDK4—skin cancer	0.000268	0.00266	CbGpPWpGaD
Danazol—GNRHR—Signaling by GPCR—PTGER4—skin cancer	0.000268	0.00266	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—MC1R—skin cancer	0.000263	0.00261	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—GLI1—skin cancer	0.000259	0.00258	CbGpPWpGaD
Danazol—AR—Integrated Pancreatic Cancer Pathway—CDK4—skin cancer	0.000258	0.00256	CbGpPWpGaD
Danazol—ESR1—Aryl Hydrocarbon Receptor—HRAS—skin cancer	0.000252	0.00251	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—GLI2—skin cancer	0.000252	0.0025	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—RHOU—skin cancer	0.000252	0.0025	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—SUFU—skin cancer	0.000246	0.00244	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—MC1R—skin cancer	0.00024	0.00239	CbGpPWpGaD
Danazol—ESR1—Integrated Breast Cancer Pathway—CDK4—skin cancer	0.00024	0.00238	CbGpPWpGaD
Danazol—CYP19A1—Integrated Breast Cancer Pathway—BRAF—skin cancer	0.000237	0.00236	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—GLI1—skin cancer	0.000237	0.00236	CbGpPWpGaD
Danazol—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—skin cancer	0.000234	0.00232	CbGpPWpGaD
Danazol—PGR—Signaling by ERBB4—NRAS—skin cancer	0.000226	0.00225	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—SUFU—skin cancer	0.000225	0.00223	CbGpPWpGaD
Danazol—ESR1—Integrated Breast Cancer Pathway—BRAF—skin cancer	0.000212	0.00211	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—PTCH2—skin cancer	0.00021	0.00208	CbGpPWpGaD
Danazol—ESR1—Integrated Pancreatic Cancer Pathway—CDK4—skin cancer	0.000199	0.00197	CbGpPWpGaD
Danazol—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—skin cancer	0.000199	0.00197	CbGpPWpGaD
Danazol—ESR1—ATF-2 transcription factor network—IL6—skin cancer	0.000198	0.00197	CbGpPWpGaD
Danazol—PGR—Signaling by ERBB4—KRAS—skin cancer	0.000194	0.00193	CbGpPWpGaD
Danazol—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—skin cancer	0.00019	0.00189	CbGpPWpGaD
Danazol—ESR1—AP-1 transcription factor network—TP53—skin cancer	0.000189	0.00188	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—SHH—skin cancer	0.000187	0.00186	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—RASA1—skin cancer	0.000186	0.00185	CbGpPWpGaD
Danazol—AR—Integrated Pancreatic Cancer Pathway—PTGS2—skin cancer	0.000184	0.00183	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—PTCH1—skin cancer	0.000178	0.00176	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—SMO—skin cancer	0.000178	0.00176	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—PTGER4—skin cancer	0.000173	0.00172	CbGpPWpGaD
Danazol—ESR1—AP-1 transcription factor network—IL6—skin cancer	0.000173	0.00172	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—SHH—skin cancer	0.000171	0.0017	CbGpPWpGaD
Danazol—ESR1—Leptin signaling pathway—HRAS—skin cancer	0.000171	0.0017	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—RASA1—skin cancer	0.00017	0.00169	CbGpPWpGaD
Danazol—PGR—Signaling by ERBB4—HRAS—skin cancer	0.000165	0.00164	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—PTCH1—skin cancer	0.000162	0.00161	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—SMO—skin cancer	0.000162	0.00161	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—GLI2—skin cancer	0.000159	0.00158	CbGpPWpGaD
Danazol—PGR—Signaling by ERBB4—IL6—skin cancer	0.000158	0.00157	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—PTGER4—skin cancer	0.000158	0.00157	CbGpPWpGaD
Danazol—CYP19A1—Metabolism—PLIN2—skin cancer	0.000155	0.00154	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—FOXO4—skin cancer	0.000153	0.00152	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—MC1R—skin cancer	0.000152	0.00151	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—GLI1—skin cancer	0.000149	0.00149	CbGpPWpGaD
Danazol—AR—Integrated Breast Cancer Pathway—KRAS—skin cancer	0.000149	0.00148	CbGpPWpGaD
Danazol—ESR1—Integrated Pancreatic Cancer Pathway—PTGS2—skin cancer	0.000142	0.00141	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—SUFU—skin cancer	0.000142	0.00141	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—FOXO4—skin cancer	0.00014	0.00139	CbGpPWpGaD
Danazol—ESR1—Signaling by ERBB4—NRAS—skin cancer	0.000133	0.00132	CbGpPWpGaD
Danazol—AR—Integrated Breast Cancer Pathway—TP53—skin cancer	0.000132	0.00132	CbGpPWpGaD
Danazol—CYP19A1—Integrated Breast Cancer Pathway—KRAS—skin cancer	0.000128	0.00127	CbGpPWpGaD
Danazol—CYP19A1—Metabolism—CSPG4—skin cancer	0.000125	0.00124	CbGpPWpGaD
Danazol—AR—Integrated Pancreatic Cancer Pathway—KRAS—skin cancer	0.000123	0.00123	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—PTCH2—skin cancer	0.000123	0.00122	CbGpPWpGaD
Danazol—AR—SIDS Susceptibility Pathways—IL6—skin cancer	0.000118	0.00117	CbGpPWpGaD
Danazol—ESR1—Integrated Breast Cancer Pathway—KRAS—skin cancer	0.000115	0.00114	CbGpPWpGaD
Danazol—ESR1—Signaling by ERBB4—KRAS—skin cancer	0.000114	0.00113	CbGpPWpGaD
Danazol—CYP19A1—Integrated Breast Cancer Pathway—TP53—skin cancer	0.000114	0.00113	CbGpPWpGaD
Danazol—AR—Integrated Pancreatic Cancer Pathway—TP53—skin cancer	0.00011	0.00109	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—SHH—skin cancer	0.000108	0.00107	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—RASA1—skin cancer	0.000107	0.00107	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—SMO—skin cancer	0.000102	0.00102	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—PTCH1—skin cancer	0.000102	0.00102	CbGpPWpGaD
Danazol—ESR1—Integrated Breast Cancer Pathway—TP53—skin cancer	0.000102	0.00101	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—TERT—skin cancer	0.000102	0.00101	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—PTGER4—skin cancer	9.97e-05	0.000991	CbGpPWpGaD
Danazol—ESR1—Signaling by ERBB4—HRAS—skin cancer	9.7e-05	0.000965	CbGpPWpGaD
Danazol—PGR—Gene Expression—ERCC2—skin cancer	9.65e-05	0.000959	CbGpPWpGaD
Danazol—ESR1—Integrated Pancreatic Cancer Pathway—KRAS—skin cancer	9.51e-05	0.000945	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—GLI2—skin cancer	9.32e-05	0.000927	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—TERT—skin cancer	9.32e-05	0.000927	CbGpPWpGaD
Danazol—ESR1—Signaling by ERBB4—IL6—skin cancer	9.28e-05	0.000923	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—MC1R—skin cancer	8.9e-05	0.000884	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—FOXO4—skin cancer	8.8e-05	0.000875	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—GLI1—skin cancer	8.77e-05	0.000872	CbGpPWpGaD
Danazol—CCL2—Signaling by GPCR—NRAS—skin cancer	8.59e-05	0.000854	CbGpPWpGaD
Danazol—CYP19A1—Metabolism—ENO2—skin cancer	8.47e-05	0.000842	CbGpPWpGaD
Danazol—ESR1—Integrated Pancreatic Cancer Pathway—TP53—skin cancer	8.45e-05	0.00084	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—SUFU—skin cancer	8.31e-05	0.000826	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—BRAF—skin cancer	8.07e-05	0.000803	CbGpPWpGaD
Danazol—GNRHR—Signaling by GPCR—NRAS—skin cancer	7.86e-05	0.000781	CbGpPWpGaD
Danazol—CCL2—Signaling by GPCR—KRAS—skin cancer	7.39e-05	0.000735	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—BRAF—skin cancer	7.38e-05	0.000734	CbGpPWpGaD
Danazol—AR—Gene Expression—ERCC2—skin cancer	7.35e-05	0.000731	CbGpPWpGaD
Danazol—GNRHR—Signaling by GPCR—KRAS—skin cancer	6.76e-05	0.000672	CbGpPWpGaD
Danazol—CYP19A1—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	6.62e-05	0.000658	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—SHH—skin cancer	6.34e-05	0.00063	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—RASA1—skin cancer	6.3e-05	0.000626	CbGpPWpGaD
Danazol—CCL2—Signaling by GPCR—HRAS—skin cancer	6.28e-05	0.000625	CbGpPWpGaD
Danazol—CCL2—Signaling by GPCR—IL6—skin cancer	6.01e-05	0.000598	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—PTCH1—skin cancer	6.01e-05	0.000597	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—SMO—skin cancer	6.01e-05	0.000597	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—TERT—skin cancer	5.88e-05	0.000585	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—PTGER4—skin cancer	5.85e-05	0.000582	CbGpPWpGaD
Danazol—GNRHR—Signaling by GPCR—HRAS—skin cancer	5.75e-05	0.000571	CbGpPWpGaD
Danazol—ESR1—Gene Expression—ERCC2—skin cancer	5.66e-05	0.000563	CbGpPWpGaD
Danazol—GNRHR—Signaling by GPCR—IL6—skin cancer	5.5e-05	0.000547	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—FOXO4—skin cancer	5.17e-05	0.000514	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—NRAS—skin cancer	5.07e-05	0.000504	CbGpPWpGaD
Danazol—CYP19A1—Metabolism—ERCC2—skin cancer	4.92e-05	0.000489	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—BRAF—skin cancer	4.66e-05	0.000463	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—NRAS—skin cancer	4.64e-05	0.000461	CbGpPWpGaD
Danazol—CYP3A4—Metabolism—PLIN2—skin cancer	4.51e-05	0.000448	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—KRAS—skin cancer	4.37e-05	0.000434	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—KRAS—skin cancer	3.99e-05	0.000397	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—TP53—skin cancer	3.88e-05	0.000386	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—HRAS—skin cancer	3.71e-05	0.000369	CbGpPWpGaD
Danazol—CYP3A4—Metabolism—CSPG4—skin cancer	3.64e-05	0.000361	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—IL6—skin cancer	3.55e-05	0.000353	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—TP53—skin cancer	3.55e-05	0.000353	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—TERT—skin cancer	3.45e-05	0.000343	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—HRAS—skin cancer	3.4e-05	0.000338	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—IL6—skin cancer	3.25e-05	0.000323	CbGpPWpGaD
Danazol—CYP19A1—Metabolism—PTGS2—skin cancer	2.95e-05	0.000293	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—NRAS—skin cancer	2.93e-05	0.000291	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—BRAF—skin cancer	2.73e-05	0.000272	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—KRAS—skin cancer	2.52e-05	0.00025	CbGpPWpGaD
Danazol—CYP3A4—Metabolism—ENO2—skin cancer	2.47e-05	0.000246	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—TP53—skin cancer	2.24e-05	0.000223	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—HRAS—skin cancer	2.14e-05	0.000213	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—IL6—skin cancer	2.05e-05	0.000204	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—NRAS—skin cancer	1.72e-05	0.000171	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—KRAS—skin cancer	1.48e-05	0.000147	CbGpPWpGaD
Danazol—CYP3A4—Metabolism—ERCC2—skin cancer	1.44e-05	0.000143	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—TP53—skin cancer	1.31e-05	0.000131	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—HRAS—skin cancer	1.26e-05	0.000125	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—IL6—skin cancer	1.2e-05	0.00012	CbGpPWpGaD
Danazol—CYP3A4—Metabolism—PTGS2—skin cancer	8.61e-06	8.56e-05	CbGpPWpGaD
